Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02380209 · ClinicalTrials.gov registry record · Early Phase 1
An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer
A Early Phase 1 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02380209 is a Early Phase 1 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 8 participants.
The verdict
NCT02380209, a Early Phase 1 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Evaluate the feasibility of translating preclinical Chemical Exchange Saturation Transfer (CEST) MRI protocol designed to estimate tumor extracellular pH (pHe) to a clinical MRI scanner in women with early stage breast cancer. Assays are used to quantify tumor acidosis.
Interventions
- OTHER CEST MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02380209
The ClinicalTrials.gov registry entry for NCT02380209 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CEST MRI is the first listed.
NCT02380209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02380209 about?
NCT02380209 is a clinical study titled "An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer". Evaluate the feasibility of translating preclinical Chemical Exchange Saturation Transfer (CEST) MRI protocol designed to estimate tumor extracellular pH (pHe) to a clinical MRI scanner in women with early stage breast cancer. Assays are used to quantify tumor acidosis.
What is the current status of trial NCT02380209?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2014-08. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02380209?
The interventions under investigation include: CEST MRI (OTHER).
Who is sponsoring clinical trial NCT02380209?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.